Literature DB >> 29363530

Topical ganciclovir treatment post-Descemet's stripping automated endothelial keratoplasty for patients with bullous keratopathy induced by cytomegalovirus.

Koji Kitazawa1,2, Passara Jongkhajornpong3, Tsutomu Inatomi4, Noriko Koizumi5, Kanae Kayukawa2, Koichi Wakimasu2, Chie Sotozono4, Shigeru Kinoshita1,2.   

Abstract

BACKGROUND/AIMS: To investigate the efficacy of topical ganciclovir (GCV) for preventing disease recurrence and improving the surgical outcome post-Descemet's stripping automated endothelial keratoplasty (DSAEK) in patients with cytomegalovirus (CMV) endotheliitis.
METHODS: This prospective, non-comparative case series study involved six eyes of six patients with endothelial decompensation due to CMV endotheliitis who underwent DSAEK, followed by a continuous, four to six times daily, topical administration of 0.5% GCV. Patient demographics, clinical history, and preoperative and postoperative examination (including any recurrence of CMV endotheliitis post-DSAEK), best corrected visual acuity (BCVA), intraocular pressure (IOP), graft survival rate and endothelial cell density (ECD) were examined.
RESULTS: No recurrence of CMV endotheliitis was detected post-DSAEK. The mean follow-up period was 40 months (range, 12-60 months). The mean preoperative BCVA was 1.52±0.68 LogMAR (range, 0.52-2.40 LogMAR), yet it had significantly improved to 0.15±0.16 LogMAR (range: -0.08 to 0.30 LogMAR) by 1 year postoperative (P<0.01). In all patients, IOP was well controlled (10-20 mm Hg) postsurgery. The mean preoperative donor ECD was 2692±177 cells/mm2, and the mean postoperative ECD was 1974, 1771 and 1174 cells/mm2 for the ECD loss of 26%, 33% and 54% at 6, 12 and 36 months, respectively. No adverse effects were observed associated with the long-term topical administration of GCV.
CONCLUSION: The continuous topical application of 0.5% GCV was found to be effective for preventing the recurrence of CMV endotheliitis, and it provided the optimal mid-term clinical outcomes post-DSAEK in patients with CMV endotheliitis. TRIAL REGISTRATION NUMBER: UMIN000026746. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Descemet’s stripping automated endothelial keratoplasty; cytomegalovirus endotheliitis; ganciclovir

Mesh:

Substances:

Year:  2018        PMID: 29363530     DOI: 10.1136/bjophthalmol-2017-311145

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  3 in total

Review 1.  Management of cytomegalovirus corneal endotheliitis.

Authors:  Angela H Y Wong; Wee Nie Kua; Alvin L Young; Kelvin H Wan
Journal:  Eye Vis (Lond)       Date:  2021-01-14

2.  Descemet stripping endothelial keratoplasty after cytomegalovirus corneal endotheliitis and immunosuppression for Mooren's ulcer.

Authors:  Koji Ueda; Takashi Ono; Tetsuya Toyono; Junko Yoshida; Toshikatsu Kaburaki; Takashi Miyai
Journal:  Am J Ophthalmol Case Rep       Date:  2021-04-14

3.  Clinical Features of Glaucoma Associated with Cytomegalovirus Corneal Endotheliitis.

Authors:  Kazuya Mori; Yunyan Ye; Hideaki Yokogawa; Tsubasa Nishino; Akira Kobayashi; Natsuko Mori; Yuko Takemoto; Kazuhisa Sugiyama
Journal:  Clin Ophthalmol       Date:  2022-08-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.